PDB Short entry for 3NU4 HEADER HYDROLASE/HYDROLASE INHIBITOR 06-JUL-10 3NU4 TITLE CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT V32I WITH ANTIVIRAL DRUG TITLE 2 AMPRENAVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 501-599; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: GAG, POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS ENZYME INHIBITION, ASPARTIC PROTEASE, HIV/AIDS, CONFORMATIONAL KEYWDS 2 CHANGE, AMPRENAVIR, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Y.-F.WANG,A.Y.KOVALEVSKY,I.T.WEBER REVDAT 4 06-SEP-23 3NU4 1 REMARK SEQADV LINK REVDAT 3 24-NOV-10 3NU4 1 JRNL REVDAT 2 08-SEP-10 3NU4 1 JRNL REVDAT 1 25-AUG-10 3NU4 0 JRNL AUTH C.H.SHEN,Y.F.WANG,A.Y.KOVALEVSKY,R.W.HARRISON,I.T.WEBER JRNL TITL AMPRENAVIR COMPLEXES WITH HIV-1 PROTEASE AND ITS JRNL TITL 2 DRUG-RESISTANT MUTANTS ALTERING HYDROPHOBIC CLUSTERS. JRNL REF FEBS J. V. 277 3699 2010 JRNL REFN ISSN 1742-464X JRNL PMID 20695887 JRNL DOI 10.1111/J.1742-4658.2010.07771.X REMARK 2 REMARK 2 RESOLUTION. 1.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 91.6 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.164 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.162 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.200 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3326 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.147 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.145 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.182 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 2576 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 51309 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1514 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 39 REMARK 3 SOLVENT ATOMS : 150 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1674.8 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1637.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 15 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 15883 REMARK 3 NUMBER OF RESTRAINTS : 20162 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 ANGLE DISTANCES (A) : 0.031 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.029 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.068 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.076 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.029 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.038 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.080 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: CONJUGATE GRADIENT MINIMIZATION REMARK 4 REMARK 4 3NU4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-JUL-10. REMARK 100 THE DEPOSITION ID IS D_1000060282. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-MAR-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 66626 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.200 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 91.6 REMARK 200 DATA REDUNDANCY : 6.100 REMARK 200 R MERGE (I) : 0.08100 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.24 REMARK 200 COMPLETENESS FOR SHELL (%) : 62.7 REMARK 200 DATA REDUNDANCY IN SHELL : 3.40 REMARK 200 R MERGE FOR SHELL (I) : 0.44200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 3NU3 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.05 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.68 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE VAPOUR DIFFUSION, HANGING DROP REMARK 280 METHOD IS APPLIED. AMPRENVIR WAS DISSOLVED IN DMSO. PROTEIN REMARK 280 CONCENTRATION IS 2.2 MG/ML. THE RATIO OF INHIBITOR TO PROTEIN IS REMARK 280 5:1 IN 0.1 M SODIUM ACETATE BUFFER (PH=5.4), WITH 0.4M NACL, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, PH 5.4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 28.88450 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.06500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.88450 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.06500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3620 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9890 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -22.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 57 CD - NE - CZ ANGL. DEV. = 15.3 DEGREES REMARK 500 ARG B 108 NE - CZ - NH1 ANGL. DEV. = 4.5 DEGREES REMARK 500 ARG B 141 NE - CZ - NH2 ANGL. DEV. = -3.3 DEGREES REMARK 500 TYR B 159 CG - CD2 - CE2 ANGL. DEV. = -5.2 DEGREES REMARK 500 ARG B 187 NE - CZ - NH1 ANGL. DEV. = 3.6 DEGREES REMARK 500 ARG B 187 NE - CZ - NH2 ANGL. DEV. = -3.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A 500 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 60 O REMARK 620 2 HOH A1058 O 94.7 REMARK 620 3 HOH A1082 O 76.6 170.8 REMARK 620 4 HOH A1114 O 98.3 76.4 101.7 REMARK 620 5 HOH A1145 O 171.3 90.2 98.8 89.8 REMARK 620 6 HOH A1180 O 96.7 92.8 91.1 162.1 75.8 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 478 B 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 503 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2IEN RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG DARUNAVIR REMARK 900 RELATED ID: 3NU3 RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I50V WITH ANTIVIRAL DRUG REMARK 900 AMPRENAVIR REMARK 900 RELATED ID: 3NU6 RELATED DB: PDB REMARK 900 MUTANT I54M HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NUJ RELATED DB: PDB REMARK 900 MUTANT I54V HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU9 RELATED DB: PDB REMARK 900 MUTANT I84V HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NUO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L90M WITH ANTIVIRAL DRUG REMARK 900 AMPRENAVIR DBREF 3NU4 A 1 99 UNP P03366 POL_HV1B1 501 599 DBREF 3NU4 B 101 199 UNP P03366 POL_HV1B1 501 599 SEQADV 3NU4 LYS A 7 UNP P03366 GLN 507 ENGINEERED MUTATION SEQADV 3NU4 ILE A 32 UNP P03366 VAL 532 ENGINEERED MUTATION SEQADV 3NU4 ILE A 33 UNP P03366 LEU 533 ENGINEERED MUTATION SEQADV 3NU4 ILE A 63 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 3NU4 ALA A 67 UNP P03366 CYS 567 ENGINEERED MUTATION SEQADV 3NU4 ALA A 95 UNP P03366 CYS 595 ENGINEERED MUTATION SEQADV 3NU4 LYS B 107 UNP P03366 GLN 507 ENGINEERED MUTATION SEQADV 3NU4 ILE B 132 UNP P03366 VAL 532 ENGINEERED MUTATION SEQADV 3NU4 ILE B 133 UNP P03366 LEU 533 ENGINEERED MUTATION SEQADV 3NU4 ILE B 163 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 3NU4 ALA B 167 UNP P03366 CYS 567 ENGINEERED MUTATION SEQADV 3NU4 ALA B 195 UNP P03366 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET NA A 500 1 HET CL A 501 1 HET 478 B 401 35 HET CL B 502 1 HET CL B 503 1 HETNAM NA SODIUM ION HETNAM CL CHLORIDE ION HETNAM 478 {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL- HETNAM 2 478 2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL HETNAM 3 478 ESTER HETSYN 478 AMPRENAVIR FORMUL 3 NA NA 1+ FORMUL 4 CL 3(CL 1-) FORMUL 5 478 C25 H35 N3 O6 S FORMUL 8 HOH *150(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 186 ILE B 193 1 8 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 198 SHEET 4 A 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 B 8 TRP A 42 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLN A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O HIS A 69 N ILE A 66 SHEET 4 B 8 THR A 31 ILE A 33 1 N THR A 31 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N ILE A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 143 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O VAL B 156 N LYS B 145 SHEET 3 C 8 HIS B 169 VAL B 177 -1 O HIS B 169 N ILE B 166 SHEET 4 C 8 ILE B 132 ILE B 133 1 N ILE B 133 O LEU B 176 SHEET 5 C 8 ILE B 184 ILE B 185 -1 O ILE B 184 N ILE B 132 SHEET 6 C 8 GLN B 118 LEU B 124 1 N LEU B 123 O ILE B 185 SHEET 7 C 8 LEU B 110 ILE B 115 -1 N ILE B 113 O LYS B 120 SHEET 8 C 8 GLY B 152 ILE B 166 -1 O GLU B 165 N LYS B 114 LINK O ASP A 60 NA NA A 500 1555 1555 2.43 LINK NA NA A 500 O HOH A1058 1555 1555 2.41 LINK NA NA A 500 O HOH A1082 1555 1555 2.51 LINK NA NA A 500 O HOH A1114 1555 1555 2.27 LINK NA NA A 500 O HOH A1145 1555 1555 2.54 LINK NA NA A 500 O HOH A1180 1555 1555 2.37 SITE 1 AC1 6 ASP A 60 HOH A1058 HOH A1082 HOH A1114 SITE 2 AC1 6 HOH A1145 HOH A1180 SITE 1 AC2 3 THR A 74 ASN A 88 ARG B 141 SITE 1 AC3 17 ASP A 25 GLY A 27 ALA A 28 ASP A 30 SITE 2 AC3 17 GLY A 48 GLY A 49 VAL A 82 HOH A1047 SITE 3 AC3 17 ASP B 125 GLY B 127 ALA B 128 ASP B 129 SITE 4 AC3 17 ASP B 130 GLY B 148 GLY B 149 ILE B 150 SITE 5 AC3 17 HOH B1001 SITE 1 AC4 1 TRP B 106 SITE 1 AC5 3 THR B 174 ASN B 188 HOH B1057 CRYST1 57.769 86.130 46.284 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017310 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011610 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021606 0.00000